Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Labopharm once-daily tramadol goal date is June 19

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The user fee goal for Labopharm's once-daily tramadol formulation is June 19, the Canadian firm says Jan. 16. The new goal date reflects Labopharm's December complete response to a Sept. 28, 2006, "approvable" letter (1Pharmaceutical Approvals Monthly October 2006, In Brief). The response contains additional analyses of existing data but no new data, the firm said. Labopharm is also appealing the letter. The June 19 user fee goal could put Labopharm behind Cipher's competing extended-release tramadol NDA, which has a May 1 action date...

You may also be interested in...



Labopharm once-daily tramadol "approvable" again

Labopharm received a second "approvable" letter May 30 for the NDA for its once-daily formulation of tramadol, the company said May 31. The new letter is FDA's answer to the December complete response the company submitted to satisfy the initial "approvable" letter it received in September (1Pharmaceutical Approvals Monthly January 2007, In Brief). Labopharm says it will discuss an "appropriate path forward" with FDA, but that it also may proceed with the Formal Dispute Resolution process it initiated in December at the same time it was responding to the September letter. Cipher's competing extended-release tramadol NDA also received an "approvable" letter in May (2Pharmaceutical Approvals Monthly May 2007, In Brief)...

Labopharm once-daily tramadol "approvable"

Labopharm may still have a chance to get its once-daily tramadol product on the market by year end if it resopnds quickly to a Sept. 28 "approvable" letter and receives a Class 1 designation for its response. The firm did not disclose the issues cited in FDA's letter, but said no additional data will be needed to address them; the NDA was submitted Nov. 28, 2005 (1Pharmaceutical Approvals Monthly December 2005, In Brief)...

Individualized Gene Therapy: US FDA Considering Device-Like Manufacturing Approval Process

CBER Director Peter Marks said the agency could streamline development by allowing sponsors to depend on an already-approved manufacturing platform and reviewing any modifications that are proposed.

UsernamePublicRestriction

Register

PS003486

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel